Skip to main content
Caplight Logo









AirNexis Therapeutics

AirNexis Therapeutics

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://airnexis.com/

Last Round

Series A

Mar 9, 2026

Est. Valuation

$341.7M

Total Funding Raised

$200M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

AirNexis Therapeutics is a biotechnology company developing clinical-stage therapies for chronic obstructive pulmonary disease (COPD) and other pulmonary conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

COPDchronic obstructive pulmonary diseaseinhaled therapybiopharmaceuticalPDE3/4 inhibitorrespiratory medicineclinical-stage biotechdrug developmentbronchodilatorsmall-molecule drugpulmonologyin-licensingclinical trialslung disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AirNexis Therapeutics Comparables

Compare AirNexis Therapeutics with similar companies based on industry and business-model similarity.

AirNexis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merck & Co., Inc.
83%
AeroRx Therapeutics
82%
Aeriant Therapeutics AB
78%

AirNexis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 9, 2026
Series AJan 9, 2026

AirNexis Therapeutics Investors

Notable investors and investment history

AirNexis Therapeutics investors
InvestorRounds
Longitude CapitalSeries A
Enavate SciencesSeries A
Life Sciences at Goldman Sachs AlternativesSeries A
OrbiMedSeries A
Frazier Life SciencesSeries A
SR OneSeries A
Goldman Sachs AlternativesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Grew 150% QoQ, from 4 to 10 employees.

  • Mar 9, 2026

    $62M round completed.

AirNexis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AirNexis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AirNexis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range10
Year Founded2026
Last FundingMar 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?